Lipids, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 25, 2025
Abstract Lipid‐lowering drugs have been used in clinics widely. It is unclear whether the an effect on renal failure. We chose high‐density lipoprotein cholesterol (ieu‐b‐109), low‐density (ieu‐a‐300), triglyceride (ieu‐b‐111), and total (ebi‐a‐GCST90038690) as exposures. SNPs near drug genes served instrumental variables. Acute failure (ARF) chronic (CRF) Europeans from GWAS catalog were selected outcomes. Datasets East Asians South for validation. Inverse variance weighted (IVW) was primary method drug‐targeted Mendelian randomization. In Europeans, people who PPARG reduced ARF risk by 69.3% (OR: 0.307, 95% CI: 0.171–0.553, p = 0.015). NPC1L1 inhibitors increased 2.684 times 2.684, 2.027–3.341, 0.003). APOE 1.987 1.987, 1.062–3.716, 0.032) but decreased CRF 49.7% 0.503, 0.283–0.894, 0.019). TNFSF12 3.866 3.866, 1.174–12.729, 0.026). Asians, 85.8% 0.142, 0.054–0.371, < 0.001). And 99.8% 0.002, 2.12e‐05‐0.179, 0.007). revealed that could reduce of Asians. cause it protective Clinicians need to consider characteristics local population before administering patients different ethnicities.
Language: Английский